drugset / Trial / NCT01511692

Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes

NCT01511692

Phase 1 Completed 43 enrolled Novo Nordisk A/S
RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in Europe and Oceania. The aim of this trial is to assess the effects of liraglutide on energy intake in subjects with type 2 diabetes.

Timeline

Start
2005-11
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glimepiride Small molecule Oral
Subject Liraglutide Peptide 1.8 mg Subcutaneous